Inovio Pharma (INO) Misses Q4 EPS by $1.13

Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.45), $1.13 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $2.84 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Iridex Corp (IRIX) Misses Q2 EPS by 5c
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41